The FDA's War Against The Truth On Ivermectin | WHAT REALLY HAPPENED X-Frame-Options: SAMEORIGIN

The FDA's War Against The Truth On Ivermectin

On July 28, the Wall Street Journal ran our article “Why Is the FDA Attacking a Safe, Effective Drug?”

In it, we outlined the potential value of the antiparasitic drug ivermectin for Covid-19, and we questioned the FDA’s vigorous attack on ivermectin. Many people praised us and many criticized us. We had clearly covered a sensitive subject. It didn’t help that one of the studies we referenced was retracted the day our article was published. Within hours of learning that fact, we sent a mea culpa to the Journal’s editors. They acted quickly, adding a note at the end of the electronic version and publishing our letter. It’s important to address two criticisms of our work. The first is that we exaggerated the FDA’s warning on ivermectin. The second is that Merck’s stance on ivermectin proved that even the company that developed ivermectin thought that it doesn’t work for Covid-19.

First, we didn’t exaggerate the FDA’s warning on ivermectin.

Instead, the agency changed its website after our article was published, probably to reflect the points we made.

Second, Merck had two incentives to downplay ivermectin’s usefulness against the novel coronavirus.

We’ll explain both points more fully.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA